The drug developer had earlier within the day reported promising outcomes from a mid-stage trial of the vaccine candidate, INO-4800.
The corporate began growing INO-4800 final yr, however fell behind rivals after the U.S. Food and Drug Administration put a portion of the examine on maintain for extra data on the vaccine supply gadget.
Inovio mentioned on Monday the medical maintain wouldn’t have an effect on the worldwide examine, including it remained on monitor to submit all paperwork to the company to raise the maintain.
The corporate is now specializing in nations the place fewer emergency vaccines can be found and are grappling with a big variety of circumstances.
On a post-earnings name, firm executives pointed to the massive unmet demand, saying solely 5% of the worldwide inhabitants acquired a Covid-19 vaccine.
Inovio is working with funders and companions to launch the worldwide trial and is assured with the progress that may enable it to expedite the examine.
Inovio reported a much bigger first-quarter lack of $54.4 million because of greater prices.
The corporate’s shares have been down 5% at $6.33 in prolonged commerce. The inventory has misplaced 45% of its worth for the reason that maintain was introduced in late-September.